| Identification | More | [Name]
Domperidone | [CAS]
57808-66-9 | [Synonyms]
4-(5-chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine
5-CHLORO-1-[1-[3-(2,3-DIHYDRO-2-OXO-1H-BENZIMIDAZOL-1-YL)PROPYL]-4-PIPERIDINYL]-1,3-DIHYDRO-2H-BENZ-IMIDAZOL-2-ONE
ALPHA-[2-(DIISOPROPYLAMINO)ETHYL]-ALPHA-PHENYL-2-PYRIDINE-ACETAMIDE
DOMPERIDONE
MOTILIUM
2h-benzimidazol-2-one,1,3-dihydro-5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1h-benzi
5-chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidaz
kw-5338
midazol-1-yl)propyl)-4-piperidinyl)-
DOMPERIDONE PERIPHERAL DOPAMINE A
3-(3-Choro Propyl)-2,3 Dihydro 1H Benzimidazole-2-One
DOMPERIDONE,BP,EP
Demperidone
5-chloro-1-(1-[3-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)propyl]piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
5-Chloro-1-[1-[3-(2，3-dihydro-2-oxo-lH-benzimidazol-1-y1)-propyl]-4-piperidyl]-1，3-dihydro-2H-benzimidazol-2-one
Euciton
Evoxin
Gastronorm
Moperidone
Nauzelin | [EINECS(EC#)]
260-968-7 | [Molecular Formula]
C22H24ClN5O2 | [MDL Number]
MFCD00069256 | [Molecular Weight]
425.91 | [MOL File]
57808-66-9.mol |
| Chemical Properties | Back Directory | [Appearance]
white powder | [Melting point ]
240-244°C | [density ]
1.2904 (rough estimate) | [refractive index ]
1.5400 (estimate) | [storage temp. ]
Store at RT | [solubility ]
DMSO: >10 mg/mL
| [form ]
solid
| [pka]
pKa 7.90 (Uncertain) | [color ]
white
| [Stability:]
Stable. Incompatible with strong oxidizing agents. | [Water Solubility ]
Slightly soluble in water. | [Merck ]
14,3418 | [InChIKey]
FGXWKSZFVQUSTL-UHFFFAOYSA-N | [CAS DataBase Reference]
57808-66-9(CAS DataBase Reference) |
| Questions And Answer | Back Directory | [Pharmacodynamics]
Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
| [Side effects]
Side effects associated with domperidone include dry mouth, abdominal cramps, diarrhea, nausea, rash, itching, hives, and hyperprolactinemia (the symptoms of which may include breast enlargement, galactorrhea, breast pain/tenderness, gynecomastia, hypogonadism, and menstrual irregularities).
| [Gastro-kinetic drugs]
Domperidone is a commonly used antiemetic and gastro-kinetic drug with its appearance being white to light yellow powder and bitter taste. It is almost insoluble in water, slightly soluble in ethanol, easily soluble in lactic acid as well as soluble in citrate. This product is a kind of peripheral dopamine receptor antagonists with strong action. Domperidone can block the DA1 and DA2 receptor next to the synapses, antagonizing the inhibitory effect of dopamine on the postsynaptic cholinergic neurons of myenteric plexus and causing the stomach contractions. It can promote the motility and tension of digestive tract motility to return to normal function, promoting the emptying of stomach, increasing the motility of gastric antral and duodenum, coordinating the contraction of the pylorus as well as enhancing the esophageal peristalsis and the tension of the lower esophageal sphincter.
Because it has a poor penetration capability through the blood-brain barrier with almost no antagonism on the dopamine receptor, you can rule out the side effects of spirit and the central nervous system side. It has rapid absorption after oral administration with the plasma concentration reaching peak after 15~30 min. In addition to the central nervous system, it is also widely distributed in other parts of the body. Owing to the presence of "first pass" hepatic metabolism and intestinal metabolism, it has a low oral bioavailability. The half-life of this product is 7h with 30% excreted through the urine at 24 h after the oral administration and about 60% excreted through faeces within 4 days.
Indications
1, Digestion dysfunction symptoms caused by delayed gastric emptying, gastroesophageal reflux, chronic gastritis and esophagitis including nausea, vomiting, belching, abdominal fullness, abdominal pain, regurgitation caused burning sensation of mouth and stomach.
2, Parkinson's disease and nausea and vomiting caused by various kinds of reasons such as functional, infection, dietary, radiotherapy or drug therapy and dopamine receptor agonists (such as levodopa, bromocriptine) therapy.
3, it is suitable for treating migraine, dysmenorrhea, traumatic brain injury and intracranial lesions, radiation therapy and the nausea and vomiting caused by levodopa, nonsteroidal anti-inflammatory drug.
4, it is effective in treating the nausea and vomiting caused by various organic or functional gastrointestinal disorders in elderly people.
5, Domperidone is not effective in treating the vomiting caused by surgery or anesthesia and chemotherapy.
The above information is edited by the Chemicalbook of Dai Xiongfeng.
| [Chemical Properties]
From dimethylformamide-water to obtain its white crystalline powder; the melting points is 242.5 ℃
| [Uses]
It is a kind of potent peripheral dopamine receptor antagonist with anti-vomiting and gastro-kinetic effects. It can affect the gastrointestinal motility to make the motility and tension of upper gastrointestinal tract return to normal and promote gastric emptying, enhancing the antral and duodenal motility, and coordinating the pyloric contraction. It can be used for the treatment of dyspepsia, and the nausea and vomiting induced by functional, organic, infection, dietary, radiation therapy or drug therapy. Because it almost has no inhibitory effect on dopamine receptor, there are no psychiatric and neurological side effects. And it can be used for treating the nausea caused by treating the Parkinson’s disease through taking dopamine agonists.
It can be used as anticholinergic antispasmodics.
Domperidone is a kind of phenyl imidazole compounds with a strong role in promoting gastric motility and antiemetic effect. It can strengthen the tension of the sphincter of the lower part of the esophagus, preventing the stomach-esophageal reflux, enhancing the gastric motility, promoting the gastric emptying, coordinating the stomach and duodenal motility, suppressing nausea, vomiting, and effectively preventing the bile reflux without affecting the secretion of gastric juice. This product is a kind of peripheral dopamine receptor antagonists which can directly block the gastrointestinal dopamine receptors and exhibit the stimulating effect of gastric motility.
It can enhance the esophageal peristalsis and the tension of esophageal sphincter. Because of its poor penetration through the blood brain barrier, it has almost no antagonism against the dopamine receptor of the brain, and therefore can excluding the side effects of the spirit and the central nervous system.
| [Production method]
2-nitro-1, 4-dichlorobenzene is reacted with 4-amino-cyclohexanecarboxylic acid ethyl ester and is further subject to hydrogenation reduction, urea cyclization, hydrolysis, to give 5-chloro-1-(piperidin-4-yl)-1,3-dihydro-benzimidazol-2-ketone.
Hydroxyl propylamine can have nucleophilic substitution of the chlorine of 2-nitro-chlorobenzene and then be subject to hydrogenation to reduce the nitro group to amino group; then have cyclization with potassium chloride and further chlorination to give 1-(3-chloropropyl)-2,3-dihydro-1H-benzimidazol-2-ketone.
The two benzimidazole derivative obtained above are processed as follows and can give domperidone. 2.3 parts of 1-(3-chloropropyl)-2,3-dihydro-1H-benzimidazol-2-ketone, 2.5 parts of 5--chloro-I-(piperidin-4-yl)-1,3-2H-dihydro-benzimidazol-2-one, 3.2 parts of sodium carbonate, 0.1 parts of potassium iodide and 80 parts of 4-methyl-2-pentanone were stirred and reflux for 24h. After being cooled to room temperature, add water, filter off the insolubles and purify it by silica gel column chromatography with the eluting solution being chloroform and 10% methanol mixture. The effluent containing the product were collected and concentrated. The residue was crystallized using 4-methyl-2-pentanone. After filtration, apply re-crystallization with the mixture of dimethylformamide and water to obtain 1.3 parts of domperidone with the yield being 30% and the mp being 242.5 ℃.
|
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R62:Possible risk of impaired fertility.
R63:Possible risk of harm to the unborn child. | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [RTECS ]
DE2275900
| [HS Code ]
29333990 |
| Hazard Information | Back Directory | [Originator]
Motilium,Cilag,Switz.,1979 | [Definition]
ChEBI: 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used
s an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet
reparations. | [Manufacturing Process]
A mixture of 2.3 parts of 1-(3-chloropropyl)-1,3-dihydro-2H-benzimidazol-2-
one, 2.5 parts of 5-chloro-1,3-dihydro-l-(4-piperidinyl)-2H-benzimidazol-2-
one, 3.2 parts of sodium carbonate, 0.1 part of potassium iodide and 80 parts
of 4-methyl-2-pentanone is stirred and refluxed for 24 hours. The reaction
mixture is cooled to room temperature and water is added. The undissolved
product is filtered off and purified by column chromatography over silica gel
using a mixture of trichloromethane and 10% methanol as eluent. The pure
fractions are collected and the eluent is evaporated. The residue is crystallized
from 4-methyl-2-pentanone. The product is filtered off and recrystallized from
a mixture of N,N-dimethylformamide and water, yielding 1.3 parts (30%) of 5-
chloro-1-[1-[3-(1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)propyl]-4-
piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; MP 242.5°C. | [Brand name]
Motilium (Janssen);Evixub;Kw 5338;Moperidona;Neta662;R 33812;Tametil;Touristic. | [Therapeutic Function]
Antiemetic | [World Health Organization (WHO)]
Domperidone, a peripheral dopaminergic antagonist, was
introduced in 1979 for the symptomatic relief of acute nausea and vomiting. The
major manufacturer became aware that the injectable formulation was being used
in some countries in much higher doses than those recommended to combat
nausea and vomiting in cancer patients treated with cytostatic agents. Such use -
which was not in conformity with the approved indications - was associated with
cardiotoxicity, which in some cases was fatal, and the manufacturer decided to
withdraw the injectable dosage form from the market worldwide in January 1985.
Suppositories, tablets and a suspension remain available and the manufacturer
continues to supply the injection for the treatment of a named patient at the written
request of a doctor on the understanding that the appropriate dosage
recommendations will be followed. | [Biological Activity]
Peripheral dopamine D 2 -like receptor antagonist that does not readily cross the blood brain barrier. Displays gastroprokinetic and antiemetic properties; increases the frequency and duration of antral and duodenal contractions and protects from apomorphine-induced emesis (ED 50 values are 0.003 and 0.03 mg/kg for i.v. and oral administration respectively). | [Clinical Use]
Acute nausea and vomiting (including that caused by
levodopa and bromocriptine)
Gastro-oesophageal reflux
Dyspepsia | [Veterinary Drugs and Treatments]
Domperidone may be useful for treatment of fescue toxicosis in
pregnant mares or as a prokinetic or antiemetic agent in small animals.
It has more effect on conditions with delayed gastric emptying
than other GI hypomotility conditions.
Via its effects on prolactin, domperidone may also be used to
stimulate milk production in horses and small animals.
Domperidone has been shown to increase plasma ACTH in
horses with equine pituitary pars intermedia dysfunction (Equine
Cushing’s) and may be useful in helping diagnose this condition. | [Drug interactions]
Potentially hazardous interactions with other drugs
Antibacterials: possible increased risk of ventricular
arrhythmias with clarithromycin, delamanid and
erythromycin - avoid with clarithromycin and
erythromycin.
Antifungals: possibly increased risk of ventricular
arrhythmias with itraconazole, ketoconazole and
voriconazole - avoid.
Antimalarials: possible increased risk of ventricular
arrhythmias with piperaquine with artenimol -
avoid.
Antivirals: possible increased risk of ventricular
arrhythmias with boceprevir; possible increased risk
of ventricular arrhythmias with ritonavir, saquinavir
and telaprevir - avoid
Apomorphine: possible increased risk of ventricular
arrhythmias.
Cobicistat: possible increased risk of ventricular
arrhythmias - avoid.
Cytotoxics: increased risk of ventricular arrhythmias
with bosutinib and ceritinib - avoid with bosutinib. | [Metabolism]
Domperidone undergoes extensive first-pass hepatic and
intestinal metabolism. It undergoes rapid and extensive
hepatic metabolism. The main metabolic pathways
are N-dealkylation by cytochrome P450 isoenzyme
CYP3A4, and aromatic hydroxylation by CYP3A4,
CYP1A2, and CYP2E1.
About 30% of an oral dose is excreted in urine within 24
hours, almost entirely as metabolites; the remainder of a
dose is excreted in faeces over several days, about 10% as
unchanged drug. | [storage]
Room temperature |
|
|